Carnitine in the treatment of valproic acid-induced toxicity

References

• CU Johannessen, SI Johannessen. 2003. Valproate: past, present, and future. CNS Drug Rev 9:199–216.
   PubMedGoogle Scholar
• MF Silva, CC Aires, PB Luis, JP Ruiter, L Ijlst, M Duran, RJ Wanders, I Tavares de Almeida. 2008. Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. J Inherit Metab Dis 31:205–216.
   PubMed Web of Science ®Google Scholar
• HA Spiller, EP Krenzelok, W Klein-Schwartz, ML Winter, JA Weber, DR Sollee, SA Bangh, JR Griffith. 2000. Multicenter case series of valproic acid ingestion: serum concentrations and toxicity. J Toxicol Clin Toxicol 38:755–760.
   PubMed Web of Science ®Google Scholar
• AC Bronstein, DA Spyker, LR CantilenaJr, J Green, BH Rumack, SE Heard. 2007. 2006 Annual report of the American Association of Poison Control Centers’ National Poison Data System (NPDS). Clin Toxicol 45:815–917.
   PubMed Web of Science ®Google Scholar
• MD Sztajnkrycer. 2002. Valproic acid toxicity: overview and management. J Toxicol Clin Toxicol 40:789–801.
   PubMed Web of Science ®Google Scholar
• R Bedry, F Parrot. 2004. Severe valproate poisoning [in French]. Réanimation 13:324–333.
   Google Scholar
• NE Flomenbaum, LR Goldfrank, RS Hoffman, MA Howland, NA Lewin, LS Nelson. eds. Goldfrank's Toxicological Emergencies. 8th ed. New York: McGraw-Hill; 2006.
   Google Scholar
• PER Lheureux, A Penaloza, S Zahir, M Gris. 2005. Science review: carnitine in the treatment of valproic acid-induced toxicity – what is the evidence?. Critical Care 9:431–440.
   PubMed Web of Science ®Google Scholar
• PR Borum, SG Bennett. 1986. Carnitine as an essential nutrient. J Am Coll Nutr 5:177–182.
   PubMed Web of Science ®Google Scholar
• G Jacobi, R Thorbeck, A Ritz, W Janssen, HL Schmidts. 1980. Fatal hepatotoxicity in child on phenobarbitone and sodium valproate. Lancet 1:712–713.
   PubMed Web of Science ®Google Scholar
• F Scaglia. Carnitine deficiency. http://www.emedicine.com/ped/topic321.htm, eMedicine 2006.
   Google Scholar
• A Evangeliou, D Vlassopoulos. 2003. Carnitine metabolism and deficit: when supplementation is necessary?. Curr Pharm Biotechnol 4:211–219.
   PubMedGoogle Scholar
• CRM Roe, SG Kahler, N Kodo, DL Norwood. Carnitine homeostatis in the organic acidurias. In: KC Tanaka. ed. Fatty Acid Oxidation: Clinical, Biochemical, and Molecular Aspects. New York: Alan R Liss; 1990: 382–402.
   Google Scholar
• DL Coulter. 1991. Carnitine, valproate, and toxicity. J Child Neurol 6:7–14.
   PubMed Web of Science ®Google Scholar
• AL Lehninger, DL Nelson, MM Cox. Oxidation of fatty acids [in French]. In Principes de Biochimie. New York: Médecine–Sciences Flammarion; 1994: 479–505.
   Google Scholar
• S DiMauro, PM DiMauro. 1973. Muscle carnitine palmityltransferase deficiency and myoglobinuria. Science 182:929–931.
   PubMed Web of Science ®Google Scholar
• CC Roe, PM Coates. Mitochondrial fatty acid oxidation disorders. In: CR Scriver, AL Beaudet, WS Sly, D Valle. eds. The Metabolic and Molecular Basic of Inherited Disease. New York: McGraw-Hill; 1995: 1501–1533.
   Google Scholar
• JV Murphy, KM Marquardt, AL Shug. 1985. Valproic acid associated abnormalities of carnitine metabolism. Lancet 1:820–821.
   PubMed Web of Science ®Google Scholar
• H Ishikura, N Matsuo, M Matsubara, T Ishihara, N Takeyama, T Tanaka. 1996. Valproic acid overdose and L-carnitine therapy. J Anal Toxicol 20:55–58.
   PubMed Web of Science ®Google Scholar
• Y Ohtani, F Endo, I Matsuda. 1982. Carnitine deficiency and hyperammonemia associated with valproic acid therapy. J Pediatr 101:782–785.
   PubMed Web of Science ®Google Scholar
• BE Gidal, CM Inglese, JF Meyer, ME Pitterle, J Antonopolous, RS Rust. 1997. Diet- and valproate-induced transient hyperammonemia: effect of L-carnitine. Pediatr Neurol 16:301–305.
   PubMed Web of Science ®Google Scholar
• J Matsumoto, H Ogawa, R Maeyama, K Okudaira, T Shinka, T Kuhara. 1997. Matsumoto I: successful treatment by direct hemoperfusion of coma possibly resulting from mitochondrial dysfunction in acute valproate intoxication. Epilepsia 38:950–953.
   PubMed Web of Science ®Google Scholar
• JY Raskind, GM El-Chaar. 2000. The role of carnitine supplementation during valproic acid therapy. Ann Pharmacother 34:630–638.
   PubMed Web of Science ®Google Scholar
• DS Millington, TP Bohan, CR Roe, AL Yergey, DJ Liberato. 1985. Valproylcarnitine: a novel drug metabolite identified by fast atom bombardment and thermospray liquid chromatographymass spectrometry. Clin Chim Acta 145:69–76.
   PubMed Web of Science ®Google Scholar
• T Sugimoto, H Muro, M Woo, N Nishida, K Murakami. 1996. Valproate metabolites in high-dose valproate plus phenytoin therapy. Epilepsia 37:1200–1203.
   PubMed Web of Science ®Google Scholar
• S Hirose, A Mitsudome, S Yasumoto, A Ogawa, Y Muta, Y Tomoda. 1998. Valproate therapy does not deplete carnitine levels in otherwise healthy children. Pediatrics 101:E9.
   PubMed Web of Science ®Google Scholar
• I Matsuda, Y Ohtani. 1986. Carnitine status in Reye and Reye-like syndromes. Pediatr Neurol 2:90–94.
   PubMedGoogle Scholar
• MF Camina, I Rozas, M Castro-Gago, JM Paz, C Alonso, S Rodriguez-Segade. 1991. Alteration of renal carnitine metabolism by anticonvulsant treatment. Neurology 41:1444–1448.
   PubMed Web of Science ®Google Scholar
• V Farkas, I Bock, J Cseko, A Sandor. 1996. Inhibition of carnitine biosynthesis by valproic acid in rats – the biochemical mechanism of inhibition. Biochem Pharmacol 52:1429–1433.
   PubMed Web of Science ®Google Scholar
• I Tein, ZW Xie. 1994. Reversal of valproic acid-associated impairment of carnitine uptake in cultured human skin fibroblasts. Biochem Biophys Res Commun 204:753–758.
   PubMed Web of Science ®Google Scholar
• FA Moreno, H Macey, B Schreiber. 2005. Carnitine levels in valproic acid-treated psychiatric patients: a cross-sectional study. J Clin Psychiatry 66:555–558.
   PubMed Web of Science ®Google Scholar
• EL Fung, NL Tang, CS Ho, CW Lam, TF Fok. 2003. Carnitine level in Chinese epileptic patients taking sodium valproate. Pediatr Neurol 28:24–27.
   PubMed Web of Science ®Google Scholar
• YG Shapiro, A Gutman. 1991. Muscle carnitine deficiency in patients using valproic acid. J Pediatr 118:646–649.
   PubMed Web of Science ®Google Scholar
• AE BryantIII, FE Dreifuss. 1996. Valproic acid hepatic fatalities. III. U.S. experience since 1986. Neurology 46:465–469.
   PubMed Web of Science ®Google Scholar
• E Björnsson. 2008. Hepatotoxicity associated with antiepileptic drugs. Acta Neurol Scand 118:281–290.
   PubMed Web of Science ®Google Scholar
• GO Andersen, S Ritland. 1995. Life threatening intoxication with sodium valproate. J Toxicol Clin Toxicol 33:279–284.
   PubMed Web of Science ®Google Scholar
• HJ Zimmerman, KG Ishak. 1982. Valproate-induced hepatic injury: analyses of 23 fatal cases. Hepatology 2:591–597.
   PubMed Web of Science ®Google Scholar
• SA Antoniuk, I Bruck, LR Honnicke, LT Martins, JE Carreiro, R Cat. 1996. Acute hepatic failure associated with valproic acid in children. Report of 3 cases [in Portuguese]. Arq Neuropsiquiatr 54:652–654.
   PubMed Web of Science ®Google Scholar
• F Berthelot-Moritz, K Chadda, I Chanavaz, JP Leroy, JM Droy, G Bonmarchand, J Leroy. 1997. Fatal sodium valproate poisoning. Intensive Care Med 23:599.
   PubMed Web of Science ®Google Scholar
• D Caparros-Lefebvre, M Lecomte-Houcke, FR Pruvot, N Declereck, JC Paris, H Petit. 1993. Unusual electronmicroscopic changes in valproate-associated liver failure. Lancet 341:1604.
   PubMed Web of Science ®Google Scholar
• N Gerber, RG Dickinson, RC Harland, RK Lynn, LD Houghton, JI Antonias, JC Schimschock. 1979. Reye-like syndrome associated with valproic acid therapy. J Pediatr 95:142–144.
   PubMed Web of Science ®Google Scholar
• SA Koenig, D Buesing, E Longin, R Oehring, P Häussermann, G Kluger, F Lindmayer, R Hanusch, I Degen, H Kuhn, K Samii, A Jungck, R Brückner, R Seitz, W Boxtermann, Y Weber, R Knapp, HH Richard, B Weidner, JM Kasper, CA Haensch, S Fitzek, M Hartmann, P Borusiak, A Müller-Deile, V Degenhardt, GC Korenke, T Hoppen, U Specht, T Gerstner. 2006. Valproic acid-induced hepatopathy: nine new fatalities in Germany from 1994 to 2003. Epilepsia 47:2027–2031.
   PubMed Web of Science ®Google Scholar
• S Gopaul, K Farrell, F Abott. 2003. Effects of age and polytherapy, risk factors of valproic acid hepatotoxicity, on the excretion of 2,4-diene VPA in people with epilepsy taking VPA. Epilepsia 44:322–328.
   PubMed Web of Science ®Google Scholar
• JO McNamara. Drugs effective in the therapy of the epilepsies. In: J Hardman, LE Limbird, PB Molinoff, RW Ruddon, AG Gilman. eds. Goodman & Gilman's the Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 1996: 476.
   Google Scholar
• FE Dreyfuss, DH Langer, KA Moline, JE Maxwell. 1989. Valproic acid fatalities II. US experience since 1984. Neurology 39:201–207.
   Google Scholar
• H Bohles, K Richter, E Wagner-Thiessen, H Schafer. 1982. Decreased serum carnitine in valproate induced Reye syndrome. Eur J Pediatr 139:185–186.
   PubMed Web of Science ®Google Scholar
• DL Coulter. 1984. Carnitine deficiency: a possible mechanism for valproate hepatotoxicity. Lancet 1:689.
   PubMed Web of Science ®Google Scholar
• DA Stumpf, WD Parker, R Haas. 1983. Carnitine deficiency with valproate therapy. J Pediatr 103:175–176.
   PubMed Web of Science ®Google Scholar
• AC Knapp, L Todesco, K Beier, L Terracciano, H Sägesser, J Reichen, S Krähenbühl. 2008. Toxicity of valproic acid in mice with decreased plasma and tissue carnitine stores. J Pharmacol Exp Ther 324:568–575.
   PubMed Web of Science ®Google Scholar
• JH Thurston, RE Hauhart. 1993. Reversal of adverse chronic effects of the unsaturated derivate of valproic acid-on ketognesis and liver coenzyme a metabolism by single injection of pantothenate, carnitine, and acetylcystein in developing mice. Pediatr Res 33:72–76.
   PubMed Web of Science ®Google Scholar
• S Krahenbuhl, G Mang, H Kupferschmidt, PJ Meier, M Krause. 1995. Plasma and hepatic carnitine and coenzyme A pools in a patient with fatal, valproate induced hepatotoxicity. Gut 37:140–143.
   PubMed Web of Science ®Google Scholar
• MC Laub, I Paetzke-Brunner, G Jaeger. 1986. Serum carnitine during valproic acid therapy. Epilepsia 27:559–562.
   PubMed Web of Science ®Google Scholar
• M Raza, AM Al-Bekairi, AM Ageel, S Qureshi. 1997. Biochemical basis of sodium valproate hepatotoxicity and renal tubular disorder: time dependence of peroxidative injury. Pharmacol Res 35:153–157.
   PubMed Web of Science ®Google Scholar
• W Tang, AG Borel, T Fujimiya, FS Abbott. 1995. Fluorinated analogues as mechanistic probes in valproic acid hepatotoxicity: hepatic microvesicular steatosis and glutathione status. Chem Res Toxicol 8:671–682.
   PubMed Web of Science ®Google Scholar
• JW Kesterson, GR Granneman, JM Machinist. 1984. The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies. Hepatology 4:1143–1152.
   PubMed Web of Science ®Google Scholar
• T Sugimoto, A Araki, N Nishida, Y Sakane, M Woo, T Takurchi, Y Kobayshi. 1987. Hepatotoxicity in rat following administration of valproic acid: effect of L-carnitine supplementation. Epilepsia 28:373–377.
   PubMed Web of Science ®Google Scholar
• KAK Shakoor. 1997. Valproic acid induced hepatotoxicitv and protective role of carnitine. Pakistan J Pathol 133–134.
   Google Scholar
• H Siemes, H Nau, K Schultze, W Wittfoht, E Drews, J Penzien, U Seidel. 1993. Valproate (VPA) metabolites in various clinical conditions of probable VPA-associated hepatotoxicity. Epilepsia 34:332–346.
   PubMed Web of Science ®Google Scholar
• DC DeVivo. 2002. Effect of L-carnitine treatment for valproate-induced hepatotoxicity. Neurology 58:507–508.
   PubMed Web of Science ®Google Scholar
• SA Konig, H Siemes, F Blaker, E Boenigk, G Gross-Selbeck, F Hanefeld, N Haas, B Kohler, W Koelfen, R Korinthenberg, et al 1994. Severe hepatotoxicity during valproate therapy: an update and report of eight new fatalities. Epilepsia 35:1005–1015.
   PubMed Web of Science ®Google Scholar
• A Romero-Falcon, E de la Santa-Belda, R Garcia-Contreras, JM Varela. 2003. A case of valproate-associated hepatotoxicity treated with L-carnitine. Eur J Intern Med 14:338–340.
   PubMedGoogle Scholar
• CK Vance, WH Vance, SC Winter, G Opala, A Szaho. 1989. Control of valproate-induced hepatotoxicity with carnitine. Ann Neurol 26:456. abstract
   Web of Science ®Google Scholar
• TP Bohan, E Helton, I McDonald, S Konig, S Gazitt, T Sugimoto, D Scheffner, L Cusmano, S Li, G Koch. 2001. Effect of L-carnitine treatment for valproate-induced hepatotoxicity. Neurology 56:1405–1409.
   PubMed Web of Science ®Google Scholar
• JV Murphy, RV Groover, C Hodge. 1993. Hepatotoxic effects in a child receiving valproate and carnitine. J Pediatr 123:318–320.
   PubMed Web of Science ®Google Scholar
• AV Chicharro, AJ Marinis, AM Kanner. 2007. The measurement of ammonia blood levels in patients taking valproic acid: looking for problems where they do not exist. Epilepsy Behav 11:361–366.
   PubMed Web of Science ®Google Scholar
• M McCall, M Bourgeois. 2004. Valproic acid-induced hyperammonemia. J Clin Psychopharmacol 24:521–526.
   PubMed Web of Science ®Google Scholar
• F Eyer, N Felgenhauer, K Gempel, W Steimer, KD Gerbitz, T Zilker. 2005. Acute valproate poisoning: pharmacokinetics, alteration in fatty acid metabolism, and changes during therapy. J Clin Psychopharmacol 25:376–380.
   PubMed Web of Science ®Google Scholar
• AL Eubanks, B Aguirre, JA Bourgeois. 2008. Severe acute hyperammonemia after brief exposure to valproate. Psychosomatics 49:82–83.
   PubMed Web of Science ®Google Scholar
• R Gugler, GE von Unruh. 1980. Clinical pharmacokinetics of valproic acid. Clin Pharmacokinet 5:67–83.
   PubMed Web of Science ®Google Scholar
• L Gram, KD Bentsen. 1985. Valproate: an updated review. Acta Neurol Scand 72:129–139.
   PubMed Web of Science ®Google Scholar
• MB Tennison, MV Miles, GM Pollack, MD Thorn, RE Dupuis. 1988. Valproate metabolites and hepatotoxicity in an epileptic population. Epilepsia 29:543–547.
   PubMed Web of Science ®Google Scholar
• DL Coulter, RJ Allen. 1980. Secondary hyperammonaemia: a possible mechanism for valproate encephalopathy. Lancet 1:1310–1311.
   PubMed Web of Science ®Google Scholar
• DM Coulter. 1981. Study of reasons for cessation of therapy with perhexiline maleate, sodium valproate and labetalol in the intensified adverse reaction reporting scheme. N Z Med J 93:81–84.
   PubMedGoogle Scholar
• PB Mortensen. 1984. Dicarboxylic acids and the lipid metabolism. Dan Med Bull 31:121–145.
   PubMed Web of Science ®Google Scholar
• K Murakami, T Sugimoto, M Woo, N Nishida, H Muro. 1996. Effect of L-carnitine supplementation on acute valproate intoxication. Epilepsia 37:687–689.
   PubMed Web of Science ®Google Scholar
• J Wadzinski, R Franks, D Roane, M Bayard. 2007. Valproate-associated hyperammonemic encephalopathy. J Am Board Fam Med 20:499–502.
   PubMed Web of Science ®Google Scholar
• A Verrotti, D Trotta, G Morgese, F Chiarelli. 2002. Valproate-induced hyperammonemic encephalopathy. Metab Brain Dis 17:367–373.
   PubMed Web of Science ®Google Scholar
• F BarruetoJr, JB Hack. 2001. Hyperammonemia and coma without hepatic dysfunction induced by valproate therapy. Acad Emerg Med 8:999–1001.
   PubMed Web of Science ®Google Scholar
• MJ Dealberto. 2007. Valproate-induced hyperammonaemic encephalopathy: review of 14 cases in the psychiatric setting. Int Clin Psychopharmacol 22:330–337.
   PubMed Web of Science ®Google Scholar
• N Segura-Bruna, A Rodriguez-Campello, V Puente, J Roquer. 2006. Valproate-induced hyperammonemic encephalopathy. Acta Neurol Scand 114:1–7.
   PubMed Web of Science ®Google Scholar
• RB Carr, K Shrewsbury. 2007. Hyperammonemia due to valproic acid in the psychiatric setting. Am J Psychiatry 164:1912–1913.
   PubMedGoogle Scholar
• L Elgudin, Y Hall, D Schubert. 2003. Ammonia induced encephalopathy from valproic acid in a bipolar patient: case report. Int J Psychiatry Med 33:91–96.
   PubMed Web of Science ®Google Scholar
• D Feil, K Chuang, DL Sultzer. 2002. Valproate-induced hyperammonemia as a cause of altered mental status. Am J Geriatr Psychiatry 10:476–478.
   PubMed Web of Science ®Google Scholar
• P Young, BC Finn, F Alvarez, JE Bruetman, H Trimarchi. 2007. Valproate-associated hyperammonemic encephalopathy. Report of one case [in Spanish]. Rev Med Chil 135:1446–1449.
   PubMed Web of Science ®Google Scholar
• CM Lokrantz, B Eriksson, I Rosen, F Asztely. 2004. Hyperammonemic encephalopathy induced by a combination of valproate and pivmecillinam. Acta Neurol Scand 109:297–301.
   PubMed Web of Science ®Google Scholar
• AM Marini, BS Zaret, RR Beckner. 1988. Hepatic and renal contributions to valproic acid-induced hyperammonemia. Neurology 38:365–371.
   PubMed Web of Science ®Google Scholar
• MC Laub. 1986. Nutritional influence on serum ammonia in young patients receiving sodium valproate. Epilepsia 27:55–59.
   PubMed Web of Science ®Google Scholar
• JM Warter, M Imler, C Marescaux, G Chabrier, L Rumbach, G Micheletti, J Krieger. 1983. Sodium valproate-induced hyperammonemia in the rat: role of the kidney. Eur J Pharmacol 87:177–182.
   PubMed Web of Science ®Google Scholar
• JM Warter, C Brandt, C Marescaux, L Rumbach, G Micheletti, G Chabrier, J Krieger, M Imler. 1983. The renal origin of sodium valproate-induced hyperammonemia in fasting humans. Neurology 33:1136–1140.
   PubMed Web of Science ®Google Scholar
• RM CollinsJr, HR Zielke, RC Woody. 1994. Valproate increases glutaminase and decreases glutamine synthetase activities in primary cultures of rat brain astrocytes. J Neurochem 62:1137–1143.
   PubMed Web of Science ®Google Scholar
• A Vittorelli, C Gauthier, C Michoudet, G Baverel. 2004. Metabolic viability and pharmaco-toxicological reactivity of cryopreserved human precision-cut renal cortical slices. Toxicol In Vitro 18:285–292.
   PubMed Web of Science ®Google Scholar
• CM Becker, RA Harris. 1983. Influence of valproic acid on hepatic carbohydrate and lipid metabolism. Arch Biochem Biophys 223:381–392.
   PubMed Web of Science ®Google Scholar
• SH Khoo, MJ Leyland. 1992. Cerebral edema following acute sodium valproate overdose. J Toxicol Clin Toxicol 30:209–214.
   PubMed Web of Science ®Google Scholar
• H Bohles, AC Sewell, D Wenzel. 1996. The effect of carnitine supplementation in valproate-induced hyperammonaemia. Acta Paediatr 85:446–449.
   PubMed Web of Science ®Google Scholar
• S Altunbasak, V Baytok, M Tasouji, O Hergüner, R Burgut, L Kayrin. 1997. Asymptomatic hyperammonemia in children treated with valproic acid. J Child Neurol 12:461–463.
   PubMed Web of Science ®Google Scholar
• D Beversdorf, C Allen, R Nordgren. 1996. Valproate induced encephalopathy treated with carnitine in an adult. J Neurol Neurosurg Psychiatry 61:211.
   PubMed Web of Science ®Google Scholar
• WN Raby. 1997. Carnitine for valproic acid-induced hyperammonemia. Am J Psychiatry 154:1168–1169.
   PubMed Web of Science ®Google Scholar
• I Borbath, T de Barsy, A Jeanjean, P Hantson. 2000. Severe hyperammonemic encephalopathy shortly after valproic acid prescription and rapid awakening following levocarnitine. J Toxicol Clin Toxicol 38:219–220.
   Google Scholar
• P Hantson, C Grandin, T Duprez, MC Nassogne, JM Guérit. 2005. Comparison of clinical, magnetic resonance and evoked potentials data in a case of valproic-acid-related hyperammonemic coma. Eur Radiol 15:59–64.
   PubMed Web of Science ®Google Scholar
• R Garnier, O Boudignat, PE Fournier. 1982. Valproate poisoning. Lancet 2:97.
   PubMed Web of Science ®Google Scholar
• SF Berkovic, PF Bladin, DB Jones, RA Smallwood, FJ Vajda. 1983. Hepatotoxicity of sodium valproate. Clin Exp Neurol 19:192–197.
   PubMedGoogle Scholar
• PB Mortensen, HE Hansen, B Pedersen, F Hartmann-Andersen, SE Husted. 1983. Acute valproate intoxication: biochemical investigations and hemodialysis treatment. Int J Clin Pharmacol Ther Toxicol 21:64–68.
   PubMedGoogle Scholar
• ES Zafrani, P Berthelot. 1982. Sodium valproate in the induction of unusual hepatotoxicity. Hepatology 2:648–649.
   PubMed Web of Science ®Google Scholar
• A Graudins, CK Aaron. 1996. Delayed peak serum valproic acid in massive divalproex overdose: treatment with charcoal hemoperfusion. J Toxicol Clin Toxicol 34:335–341.
   PubMed Web of Science ®Google Scholar
• JGV Van Keulen, RJ Gemke, JAE Van Wijk, DJ Touw. 2000. Treatment of valproic acid overdose with continuous arteriovenous hemofiltration [abstract]. J Toxicol Clin Toxicol 38:219.
   Google Scholar
• LK Hicks, PA McFarlane. 2001. Valproic acid overdose and haemodialysis. Nephrol Dial Transplant 16:1483–1486.
   PubMed Web of Science ®Google Scholar
• CP Guillaume, L Stolk, TF Dejagere, JP Kooman. 2004. Successful use of hemodialysis in acute valproic acid intoxication. J Toxicol Clin Toxicol 42:335–336.
   PubMedGoogle Scholar
• V Minville, C Roche Tissot, K Samii. 2004. Haemodialysis, L-carnitine therapy and valproic acid overdose [in French]. Ann Fr Anesth Reanim 23:357–360.
   PubMed Web of Science ®Google Scholar
• YC Chan, ML Tse, FL Lau. 2007. Two cases of valproic acid poisoning treated with L-carnitine. Hum Exp Toxicol 26:967–969.
   PubMed Web of Science ®Google Scholar
• J Jung, E Eo, KO Ahn. 2008. A case of hemoperfusion and L-carnitine management in valproic acid overdose. Am J Emerg Med 26:388. e3–4
   PubMed Web of Science ®Google Scholar
• F LoVecchio, J Shriki, R Samaddar. 2005. L-carnitine was safely administered in the setting of valproate toxicity. Am J Emerg Med 23:321–322.
   PubMed Web of Science ®Google Scholar
• S Russell. 2007. Carnitine as an antidote for acute valproate toxicity in children. Curr Opin Pediatr 19:206–210.
   PubMed Web of Science ®Google Scholar
• DC De Vivo, TP Bohan, DL Coulter, FE Dreifuss, RS Greenwood, DR NordliJr, WD Shields, CE Stafstrom, I Tein. 1998. L-carnitine supplementation in childhood epilepsy: current perspectives. Epilepsia 39:1216–1225.
   PubMed Web of Science ®Google Scholar
• M Samuels. Manual of Neurologic Therapeutics. Philadelphia: Lippincott, Williams & Wilkins; 1999.
   Google Scholar
• AACE Nutrition Guidelines Task Force. 2003. American association of clinical endocrinologists medical guidelines for the clinical use of dietary supplements and nutraceuticals. Endocr Pract 9:417–470.
   PubMedGoogle Scholar
• F Lammert, S Matern. 1997. Hepatic diseases caused by drugs [in German]. Schweiz Rundsch Med Prax 86:1167–1171.
   Google Scholar